Electronic Medicines Compendium (emc)
Foundayo is now the second oral GLP-1 medication available for weight management, following the approval of oral Wegovy (semaglutide) in December 2025
Second, it includes the two largest single-product revenue streams ever to face LOE in a short time window, Keytruda and Eliquis, within approximately the same 36-month period
The most suitable option depends on individual needs, but there is limited evidence that one form provides greater weight loss benefits alongside Mounjaro
Glossitis (inflamed tongue) usually resolves within two to three weeks, and patients report reduced oral discomfort
After this initial period, the dose is increased to 5 mg weekly, with subsequent escalations by 2.5 mg increments every four weeks as tolerated, up to a maximum of 15 mg weekly based on glycemic response and tolerability